

JENOPTIK AG – First nine months 2022

Dr. Stefan Traeger I Hans-Dieter Schumacher | November 10, 2022

Disclaimer




This presentation can contain forward-looking statements that are based on current expectations and certain assumptions of the management of the Jenoptik Group. A variety of known and unknown risks, uncertainties and other factors can cause the actual results, the financial situation, the development or the performance of the company to be materially different from the announced forward-looking statements. Such factors can be, among others, geopolitical conflicts, pandemic diseases, changes in currency exchange rates and interest rates, energy supply, the introduction of competing products or the change of the business strategy. The company does not assume any obligation to update such forward-looking statements in this document in the light of future developments.



Highlights Nine months 2022

Highlights in the first nine months of 2022





- Groundbreaking ceremony for new high-tech fab in Dresden, investment of more than 70 million euros
- Sale of VINCORION (mechatronics business / defense) successfully closed on June 30, 2022, major milestone achieved in transformation into a globally leading pure photonics player
- Sustained strong momentum in particular in the semiconductor equipment business drives order intake and revenue
- Strong organic growth of 11.9% of the continuing operations
- Significant increase in profitability on a comparable basis with an EBITDA margin of 16.9% (prior year 16.2% without one-off effect)
- Free cash flow grew to 28.4 million euros in spite of higher capital expenditure (prior year 11.1 million euros)
- Guidance for full year 2022 specified




Nine months 2022 Continuing operations

Strong development of order intake and backlog continued in third quarter 2022 – setting very good stage for further growth




Order intake in million euros



- Advanced Photonic Solutions division with significant increase in order intake (incl. contribution by former Jenoptik Medical (before BG Medical) and the SwissOptic Group), Smart Mobility Solutions also received more orders
- Book-to-bill ratio of 1.27 (prior year 1.29)

Order backlog in million euros




- Order backlog substantially higher than at year end 2021
- Ca. 33% to be converted to revenue in 2022 (prior year 50.1%)

Strong organic growth and contributions from the acquired companies resulted in significant revenue growth



Revenue in million euros




- Continuing operations showed strong organic growth of 11.9%
- Advanced Photonic Solutions division grew significantly due to strong organic growth and revenue contribution from former Jenoptik Medical and the SwissOptic Group
- Revenue of the Smart Mobility Solutions division exceeded prior-year figure
- Revenue of Non-Photonic Portfolio Companies lower than in prior year






EBITDA in million euros



- Strong operating performance of Advanced Photonic Solutions;
 in prior year one-off effect of 25.6 million euros in connection
 with acquisitions of TRIOPTICS and INTEROB included
- PPA of minus 1.3 million euros (prior year minus 1.8 million euros)
- EBITDA margin of 16.9% (prior year 16.2% without one-off effect;
 21.1% including one-off effect)

EBIT in million euros



- EBIT decline due to one-off effect in prior year
- PPA of minus 20.4 million euros (prior year minus 12.1 million euros)
- EBIT margin of 9.8% (prior year 9.4% without one-off effect;
 14.3% incl. one-off effect)

Statement of income



In million euros	9M/2022	9M/2021
Revenue	698.0	519.5
Gross margin	34.1%	33.3%
Functional costs	169.5	132.3
Other operating result (incl. impairment gains and losses)	-0.2	33.6
EBIT	68.4	74.3
Financial result	-3.6	-4.9
Earnings before tax	64.8	69.4
Income taxes	-18.6	-6.9
Earnings after tax (Group); of which discontinued operation	41.4 -4.8	66.2
Earnings per share (euros; Group)	0.71	1.12

- Gross margin improved in spite of higher material and personnel costs
- Functional costs increased less than revenue in spite of inclusion of companies acquired in 2021
 - R+D expenses: 38.5 million euros (prior year 28.2m euros),
 R+D output: 63.9 million euros (prior year 45.8m euros)
 - Selling expenses: 78.7 million euros (pr. year 64.6m euros)
 - Administrative expenses: 52.2 million euros (prior year 39.5m euros)
- Other operating result declined substantially as prior-year figure included positive one-off effect in connection with conditional purchase price components from acquisitions of TRIOPTICS and INTEROB
- Tax rate of 28.7% (prior year 9.9%) due to changed regional profit distribution and deferred tax expense resulting from utilization of tax loss carryforwards; cash-effective tax rate of 16.0% (prior year 14.5%)
- Group earnings after tax lower, mainly due to positive one-off effect in prior year, prior-year EPS without one-off was 0.68 euros

Jenoptik is well positioned for future growth with sound financial base and balance sheet structure



In million euros	9M/2022	9M/2021
Earnings before tax*	60.9	74.9
In particular depreciation/amortization, non-cash income/expenses, changes in working capital*	24.7	-25.6
Cash flows from operating activities before income taxes*	85.7	49.4
Cash flows from operative investing activities*	-59.0	-31.6
Free cash flow (before interest and taxes)*	26.7	17.7
Of which continuing operations	28.4	11.1

^{*} Group

Group

- Cash flows from operating activities increased due to significantly higher earnings before non-cash effects and lower effects from building up working capital
- Equity ratio improved to 48.9% compared with year end 2021 (31.12.21: 44.4%)
- Net debt reduced to 520.3 million euros (31.12.21: 541.4m euros)

Continuing operations

- Working capital grew to 294.4 million euros, in particular due to increase in inventories (31.12.21: 260.6m euros)
 Working capital ratio: 31.7% (31.12.21: 34.7%) former Jenoptik Medical and the SwissOptic Group included pro rata in revenue but fully in balance sheet items
- Investments significantly increased to 65.9 million euros (prior year 27.8m euros)
- Free cash flow grew to 28.4 million euros (prior year 11.1m euros), in spite of higher investments




Nine months 2022 Divisions

Advanced Photonic Solutions: very positive operational development continued in 3rd quarter



- Strong organic revenue growth of 18.0%; revenue with semiconductor equipment industry and in biophotonics and optical test & measurement areas grew substantially; former Jenoptik Medical and the SwissOptic Group contributed 117.8 million euros
- EBITDA markedly improved due to very good operating performance (in prior year one-off effect of 25.6 million euros from acquisitions of TRIOPTICS and INTEROB included)
- Order intake: continuing strong demand from semiconductor equipment industry,
 biophotonics and industrial solutions; acquired companies contributed 156.1 million euros;
 book-to-bill ratio: 1.27 (prior year 1.34); high order backlog
- Free cash flow higher than in prior year despite significantly higher investments

In million euros	9M/2022	9M/2021	Change in %
Revenue	529.1	349.6	51.4
EBITDA	123.5	106.0	16.5
EBITDA margin in %	23.3	30.2	n/a
EBIT	89.8	87.5	2.7
FCF	63.4	56.2	12.8
Order intake	670.5	467.1	43.5
Order backlog	588.9	430.2*	36.9



*31.12.2021





- Increase in revenue in the first nine months of 2022 and quarter-over-quarter –
 21.2m euros in Q1, 23.5m euros in Q2 and increase to 31.2m euros in Q3
- EBITDA slightly lower than in prior year, in part due to higher R+D and selling expenses
- Order intake grew; larger orders from North America, Europe, South America and the Middle East/Africa included (in Q1/2021 several orders of around 20 million euros received in North America);

book-to-bill ratio: 1.35 (prior year 1.20)

Free cash flow improved (in prior year high payments for working capital)

In million euros	9M/2022	9M/2021	Change in %
Revenue	75.8	72.3	4.8
EBITDA	8.4	8.6	-2.3
EBITDA margin in %	11.1	11.9	n/a
EBIT	4.4	3.5	26.0
FCF	0.0		n/a
Order intake	102.6	86.7	18.4
Order backlog	83.3	54.3*	53.5



*31.12.2021

Non-Photonic Portfolio Companies: order backlog markedly higher than at year end 2021



- Revenue below prior-year level (in prior year revenue contribution from non-optical process metrology business included); increase in the automation area
- Earnings and margin lower than in prior year, in part due to projects in automation area (in prior year proceeds from sale of metrology business mentioned above)
- Order intake decreased slightly compared with the high prior-year figure (automation orders of more than 40 million USD received in North America in Q1/2021);
 metrology area showed growth; book-to-bill ratio: 1.20 (prior year 1.17)
- Increase in free cash flow due to higher cash flows from operating activities

In million euros	9M/2022	9M/2021	Change in %
Revenue	91.1	96.0	-5.2
EBITDA	-2.8	4.4	n/a
EBITDA margin in %	-3.0	4.6	n/a
EBIT	-9.8	-3.1	
FCF	4.4	-12.8	n/a
Order intake	109.3	112.6	-2.9
Order backlog	77.4	58.9*	31.4
			*24.42.2024

*31.12.2021





Outlook

Outlook for 2022 specified



Fiscal year 2022: Further profitable growth expected

Our scheduled growth presupposes that the geopolitical risks do not worsen further. This includes, among other things, the Ukraine conflict – with the sanctions that have been implemented and potential impacts on price developments, energy supply and supply chains. Uncertainties also exist with regard to the development of the Covid-19 pandemic, inflation and continuing supply bottlenecks, although Jenoptik is confident to be able to manage them.

Expected development of key performance indicators in 2022 (continuing operations)

- Revenue expected in the upper half of the existing range of 930 to
 960 million euros (incl. former Jenoptik Medical and SwissOptic Group) /
 2021: 750.7m euros)
- Substantial growth in EBITDA; EBITDA margin still expected between
 18.0 and 18.5% (2021: 16.7% excl. one-off effects)

Jenoptik's outlook is based in particular on: good order situation, well-filled project pipeline as well as an ongoing promising development in the core photonics business, in particular in the semiconductor equipment sector.



Appendix

Dates and contact





10.11.2022

15.11.2022

06.12.2022

05.-06.01.2023

15.02.2023

Quarterly Statement January – September 2022

BNP Paribas Exane 5th MidCap CEO Conference, Paris

Berenberg European Conference 2022, Penny Hill

ODDO BHF Forum, Lyon

Preliminary figures of fiscal year 2022



Andreas Theisen

Head of Investor Relations JENOPTIK AG

Phone: +49 3641 65-2291 andreas.theisen@jenoptik.com

Sabine Barnekow

Investor Relations Manager JENOPTIK AG

Phone: +49 3641 65-2156 sabine.barnekow@jenoptik.com

www.jenoptik.com www.twitter.com/Jenoptik_Group https://www.linkedin.com/company/jenoptik/ https://www.instagram.com/jenoptik_morelight/